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Abstract: Objective Obesity is associated with low-grade adipose tissue inflammation and locally elevated
levels of several glycoprotein 130 (gp130) cytokines. The conversion of white into brown-like adipocytes
(browning) may increase energy expenditure and revert the positive energy balance that underlies obesity.
Although different gp130 cytokines and their downstream targets were shown to regulate expression of
the key browning marker uncoupling protein 1 (Ucp1), it remains largely unknown how this contributes to
the development and maintenance of obesity. Herein, we aim to study the role of gp130 cytokine signaling
in white adipose tissue (WAT) browning in the obese state. Methods Protein and gene expression levels
of UCP1 and other thermogenic markers were assessed in a subcutaneous adipocyte cell line, adipose
tissue depots from control or adipocyte-specific gp130 knockout (gp130Δadipo) mice fed either chow or
a high-fat diet (HFD), or subcutaneous WAT biopsies from a human cohort of lean and obese subjects.
WAT browning was modelled in vitro by exposing mature adipocytes to isoproterenol subsequent to
stimulation with gp130 cytokines. ERK and JAK-STAT signaling were blocked using the inhibitors
U0126 and Tofacitinib, respectively. Results Inguinal WAT of HFD-fed gp130Δadipo mice exhibited
significantly elevated levels of UCP1 and other browning markers such as Cidea and Pgc-1฀. In vitro,
treatment with the gp130 cytokine oncostatin M (OSM) lowered isoproterenol-induced UCP1 protein
and gene expression levels in a dose-dependent manner. Mechanistically, OSM mediated the inhibition
of Ucp1 via the JAK-STAT but not the ERK pathway. In line with mouse data, OSM gene expression
in human WAT positively correlated with BMI (r=0.284, p=0.021, n=66) and negatively with UCP1
expression (r=-0.413, p<0.001, n=66). Conclusions Our data support the notion that OSM negatively
regulates thermogenesis in WAT and, thus, may be an attractive target to treat obesity.
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Objective Obesity is associated with low-grade adipose tissue inflammation and locally 
elevated levels of several glycoprotein 130 (gp130) cytokines. The conversion of white 
into brown-like adipocytes (browning) may increase energy expenditure and revert the 
positive energy balance that underlies obesity. Although different gp130 cytokines and 
their downstream targets were shown to regulate expression of the key browning marker 
uncoupling protein 1 (Ucp1), it remains largely unknown how this contributes to the 
development and maintenance of obesity. Herein, we aim to study the role of gp130 
cytokine signaling in white adipose tissue (WAT) browning in the obese state. 
Methods Protein and gene expression levels of UCP1 and other thermogenic markers 
were assessed in a subcutaneous adipocyte cell line, adipose tissue depots from control 
or adipocyte-specific gp130 knockout (gp130Δadipo) mice fed either chow or a high-fat diet 
(HFD), or subcutaneous WAT biopsies from a human cohort of lean and obese subjects. 
WAT browning was modelled in vitro by exposing mature adipocytes to isoproterenol 
subsequent to stimulation with gp130 cytokines. ERK and JAK-STAT signaling were 
blocked using the inhibitors U0126 and Tofacitinib, respectively. 
Results Inguinal WAT of HFD-fed gp130Δadipo mice exhibited significantly elevated levels 
of UCP1 and other browning markers such as Cidea and Pgc-1α. In vitro, treatment with 
the gp130 cytokine oncostatin M (OSM) lowered isoproterenol-induced UCP1 protein and 
gene expression levels in a dose-dependent manner. Mechanistically, OSM mediated the 
inhibition of Ucp1 via the JAK-STAT but not the ERK pathway. In line with mouse data, 
OSM gene expression in human WAT positively correlated with BMI (r=0.284, p=0.021, 











Conclusions Our data support the notion that OSM negatively regulates thermogenesis 
in WAT and, thus, may be an attractive target to treat obesity. 
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Obesity manifests upon a sustained positive energy balance throughout which 
excess energy is stored in white adipose tissue (WAT) depots. The key to reversing 
obesity therefore lies in attaining a negative energy balance. Brown adipocytes can 
dissipate energy through non-shivering thermogenesis, an essential process to maintain 
core temperature requiring uncoupling protein 1 (UCP1). Besides cold exposure-mediated 
stimulation of β-adrenergic receptors, which is the main physiological stimulus to activate 
brown adipose tissue (BAT), a large number of alternative stimuli including exercise and 
specific diets have been reported (1; 2). However, since obese individuals seem to have 
rather small amounts of functional BAT (3-5), it may be more promising to target their 
WAT depots instead. Namely, WAT can be harnessed to burn rather than store energy by 
conversion of white into brown-like adipocytes (browning). Consequently, the focus of 
obesity research on WAT browning has gained substantial momentum over the past 
decade (6). Despite huge efforts, only a small number of drugs with proven or presumed 
effects on WAT browning are presently available in clinic (7), making the search for better 
alternatives imperative. 
The expansion of adipose tissue depots is paralleled by an invasion of immune cells 
that concomitantly leads to a state of low-grade inflammation (8). Immune cells 
communicate with adipocytes and modulate their metabolic functions via the secretion of 
pro-inflammatory cytokines. The glycoprotein 130 (gp130) cytokine family comprises a 
main subgroup of such cytokines that consists of interleukin (IL)-6, IL-11, IL-27, IL-35, 
cardiotrophin-1, cardiotrophin-like cytokine, ciliary neurotrophic factor, leukemia inhibitory 
factor and oncostatin M (OSM). Although each of these cytokines has a unique receptor 











of at least one gp130 subunit making gp130 the common signal transducer for all family 
members (9; 10). The two key intracellular signaling cascades activated by all gp130 
cytokines are the extracellular signal-regulated kinase (ERK) and Janus kinase (JAK)-
signal transducer and activator of transcription (STAT) pathways (11). As such, gp130 
cytokines can influence a plethora of metabolic processes. For instance, making use of 
mice that lacked the gp130 protein specifically in adipocytes (gp130Δadipo mice), we 
previously unveiled that gp130 cytokine signaling regulates free-fatty acid and leptin 
release in WAT, thereby indirectly affecting insulin release from pancreatic islets (12; 13). 
Interestingly, several signaling molecules upstream as well as downstream of the gp130 
signaling complex have been related to WAT browning. For example, activation of both 
the ERK and the JAK-STAT pathway in adipocytes was associated with either positive or 
negative changes in WAT browning (14-17). Furthermore, the gp130 cytokines IL-6 and 
OSM were linked to more and less UCP1 expression in WAT, respectively (18-20). 
Although they are both elevated in WAT under obesity (20; 21), their role in WAT browning 
in the latter condition remains largely unknown. Herein, we explored the role of gp130 
signaling in WAT browning in the obese state using previously characterized gp130Δadipo 
mice. Moreover, by performing experiments in cultured white adipocytes and in human 
WAT, we aimed to shed light on the opposing claims of up- and downstream players of 











2. Material and Methods 
2.1 Human samples 
We included 159 individuals with a wide range of BMI (19-73 kg/m²), type 2 diabetes 
(n=84) and normal glucose metabolism (n=75). Paired abdominal subcutaneous adipose 
tissue biopsies were taken during elective sleeve gastrectomy, Roux-en-Y gastric bypass, 
hernia or cholecystectomy surgeries and processed as previously described (22). The 
study was approved by the Ethics Committee of the University of Leipzig (approval no: 
159-12-21052012), and performed in accordance to the declaration of Helsinki. All 
subjects gave written informed consent before taking part in this study. RNA from adipose 
tissue was extracted by using RNeasy Lipid tissue Mini Kit (Qiagen, Hilden, Germany). 
Quantity and integrity of RNA was monitored with NanoVue plus Spectrophotometer (GE 
Healthcare, Freiburg, Germany). 1 µg total RNA from subcutaneous adipose tissue was 
reverse-transcribed with standard reagents (Life technologies, Darmstadt, Germany). 
cDNA was then processed for TaqMan probe-based quantitative real-time polymerase 
chain reaction (qPCR) using the QuantStudio 6 Flex Real-Time PCR System (Life 
technologies, Darmstadt, Germany). Expression of OSM, UCP1, and IL-6 were calculated 
by standard curve method and normalized to the expression of hypoxanthine guanine 
phosphoribosyltransferase 1 (HPRT1) as a housekeeping gene. The probes (Life 
technologies, Darmstadt, Germany) for OSM (Hs00171165_m1), UCP1 
(Hs00222453_m1), IL-6 (Hs00985639_m1) and HPRT1 (Hs01003267_m1) span exon-
exon boundaries to improve the specificity of the qPCR. For analysis, only subjects in 













2.2 Mouse samples 
To obtain gp130Δadipo mice, gp130F/F mice (23) were crossed with Adipoq-Cre mice 
(The Jackson Laboratory, Bar Harbor, ME, USA) as described (12). Littermate mice with 
floxed gp130 but absent Cre-recombinase (Cre) expression were used as controls 
(gp130F/F). Every animal was considered an experimental unit. Animals were housed in 
groups of 2-5 in a specific pathogen-free, temperature-controlled environment (±22°C) 
with a 12 h light/12 h dark cycle and crinkles as bedding material. Mice received standard 
chow diet (ProvimiKliba, Kaiseraugst, Switzerland) or were switched to HFD (D12331; 
Research Diets, New Brunswick, NJ, USA) at the age of 6 weeks. Animals were allocated 
to diets based on body weight (similar mean +/- SD in starting body weight between the 
groups). Water was provided ad libitum. Experimenters were not blinded to the identity of 
a specific mouse. Adipose tissue samples were harvested from 18-week-old male mice 
after a 5-hour fasting period. Samples were snap-frozen and stored at -80°C. Experiments 
were performed according to Swiss animal protection laws and approved by the cantonal 
veterinary office in Zurich, Switzerland. 
 
2.3 Cell culture and treatments  
Previously characterized murine subcutaneous white pre-adipocytes (24) or 3T3-L1 
cells were plated in 12- or 24-well plates coated with 0.1% wt/vol. gelatin (Bio-Rad 170-
6537). Cells were maintained in complete medium (CM) consisting of DMEM (25 mmol/l 
glucose) supplemented with 10% vol./vol. fetal bovine serum and 1% vol./vol. 
penicillin/streptomycin (all from Invitrogen, Basel, Switzerland) that was changed every 2-
3 days. Differentiation towards mature adipocytes started two days after reaching 











(500 μmol/l), dexamethasone (1 μmol/l), insulin (1.7 μmol/l) and rosiglitazone (1 μmol/l). 
The next 2 days cells were cultured in CM with insulin (0.5 μmol/l). Experiments with 
subcutaneous adipocytes were commenced after another 2 days in CM without further 
supplements. Differentiation of 3T3-L1 cells, cultivation of RAW 264.7 cells, and isolation 
of adipocytes and stromal vascular fraction (SVF) was performed as previously described 
(25; 26).  
Fully differentiated adipocytes were treated with vehicle or various concentrations of 
OSM (495-MO, R&D systems, Zug, Switzerland), IL-6 (AG-40B-0108, AdipoGen, Liestal, 
Switzerland) or leptin (498-OB, R&D systems, Zug, Switzerland) for up to 24 hours as 
indicated in the figure legends. Browning was induced by 3 or 6 hours treatment with 1 or 
10 μmol/l isoproterenol as indicated. For inhibitor experiments, cells were pre-treated for 
1 hour with 50 μmol/l U0126 (ab120241, Abcam, Cambridge, UK), 2 μmol/l Tofacitinib 
(CP-690550, LuBioScience GmbH, Zurich, Switzerland), or a vehicle. Isolated SVF cells 
or cultured RAW cells were treated with 10 ng/ml lipopolysaccharides (LPS; Sigma-
Aldrich, Buchs, Switzerland) for 6 hours. 3T3-L1 cells were treated with 100 nM human 
insulin (Actrapid, Novo Nordisk Pharma AG, Zurich, Switzerland) for 10 minutes. Cells 
were harvested after a brief wash in ice-cold PBS. Cell culture data represent at least two 
biological replicates and each condition was generally performed in duplicates. Cells were 
not tested for mycoplasma contamination. Experimenters were not blinded to the identity 
of a specific sample. 
 
2.4 Protein lysis and western blot analysis  
Tissues or cells were lysed in a buffer containing 150 mmol/l NaCl, 50 mmol/l Tris-











mmol/l sodium pyrophosphate, 1 mmol/l sodium vanadate, 1 mmol/l NaF, 10 mmol/l 
sodium β-glycerolphosphate, 0.2 mmol/l PMSF and 0.1% vol./vol. protease inhibitor 
cocktail (Sigma-Aldrich, Buchs, Switzerland). Protein concentrations were determined 
with a BCA assay (Pierce, Rockford, IL, USA). Equal amounts of protein were resolved 
using SDS-PAGE and electro-transferred onto 0.2 μm nitrocellulose membranes (BioRad, 
Reinach, Switzerland). Equal loading of proteins was verified by Ponceau S staining. Blots 
were blocked with 5% wt/vol. dry fat milk dissolved in tris-buffered saline (150 mmol/l 
NaCl, 50 mmol/l Tris-HCl) containing 0.1% vol./vol. Tween (TBS-T). Membranes were 
incubated overnight at 4°C with primary antibody diluted in TBS-T supplemented with 5% 
wt/vol. bovine serum albumin and 0.02% wt/vol. sodium azide followed by 1 hour 
incubation at room temperature with a secondary antibody diluted in TBS-T with 5% wt/vol. 
dry fat milk. Membranes were developed using the ECL system and antibody-antigen 
complexes were detected with a ChemiDocTM MP Imaging System (Biorad, Reinach, 
Switzerland). Primary antibodies were used at a dilution of 1:1000 unless specified and 
include: UCP1, PA1-24894 (Thermofisher Scientific, Waltham, MA, USA); pAkt (Thr308), 
#13038; Akt, #9272; pERK1/2, #9101; ERK1/2, #9211; pSTAT3, #9145; STAT3, #9132 
(Cell Signaling, Danvers, MA, USA); PPARγ, sc-7196 (1:200, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA); and Actin, MAB1501 (Millipore, Darmstadt, Germany). Molecular 
weight/pattern of bands was compared to existing literature when possible. Details of 
antibodies used such as data sheets, citations and reviews can be found via antibody 
above listed catalogue numbers. Secondary antibodies, diluted 1:5000, are goat-anti-













2.5 RNA extraction and RT-qPCR analysis 
Total RNA was extracted from homogenized tissues with the NucleoSpin® RNA Set 
for NucleoZOL or from cells with NucleoSpin® RNA isolation kit (Macherey-Nagel, Düren, 
Germany). RNA concentration was determined with NanoDrop® (ThermoFisher 
Scientific, Waltham, MA, USA). Equal amounts of RNA (50-500 ng) were reverse-
transcribed with the GoScript™ Reverse Transcription System (Promega, Madison, WI, 
USA) and cDNA was amplified by real-time PCR using the following probes/primers: 
Ucp1, Mm0124486_m1; Cidea, Mm00432554_m1; Ppargc1a, Mm01208835_m1; 
Prdm16, Mm00712556_m1; Dio2, Mm00515664_m1; Pparg, Mm00440940_m1; Ppara, 
Mm00627559_m1; Tbx1, Mm00448949_m1; Tmem26, Mm01173641_m1; Osm, 
Mm01193966_m1; gp130 (Il6st), Mm00439665_m1; 18s, 4352930 (Applied Biosystems, 
Rotkreuz, Switzerland). Autotaxin (Enpp2), Fw: GACCCTAAAGCCATTATTGCTAA, Rv: 
GGGAAGGTGCTGTTTCATGT (27); Probe: AAACCAGATCAGCACTTTAAGCC 
(Microsynth, Balgach, Switzerland). Relative gene expression values were obtained after 
normalization to 18s using the 2-ΔΔCt method. Outliers defined as values exceeding 2 SD 
from the mean were excluded. 
 
2.6 Hematoxylin-eosin and Oil-Red-O staining  
Inguinal snap-frozen tissues were fixed overnight in 4% buffered formalin, 
dehydrated and embedded in paraffin blocks. Four micrometer thick sections were cut 
and stained for hematoxylin and eosin. For Oil-Red-O staining, cells were fixed in 4% 
wt/vol. paraformaldehyde solution (AppliChem, Darmstadt, Germany) for 30 minutes on 
ice, rinsed in dH2O and dehydrated in 60% vol./vol. isoproterenol. Cells were stained with 











dissolved in 100% isoproterenol that was freshly diluted to 60% vol./vol. in dH2O. After 5-
10 minutes, cells were rinsed twice in dH2O. Tissue slices or cells were imaged using an 
Axio Observer microscope platform (Zeiss, Jena, Germany). Tile scans were analyzed 
with ImageJ software to calculate the Oil-Red-O positive signal per well. 
 
2.7 Data analysis 
Date are presented as means ± SE. Statistics were calculated using GraphPad 
Prism 8.00 (GraphPad Software, San Diego, CA, USA) by means of a paired or unpaired 
two-tailed Student’s t-test (for normally distributed data), Mann-Whitney test (for not 
normally distributed data), one-way ANOVA with Tukey multiple comparisons correction, 
or linear regression analysis. A p-value < 0.05 was considered statistically significant. 
Power calculation analysis was not performed. Sample size was determined based on 
previous experiments performed in our laboratory. 
 
2.8 Data and resource availability 
The data supporting the findings of this study are available within the article, its 
Supplementary Information files or from the corresponding author upon reasonable 













3.1 Increased browning in ingWAT of HFD-fed gp130Δadipo mice 
To test the hypothesis that gp130 plays a role in WAT browning, we examined the 
levels of UCP1 in white fat depots obtained from our previously characterized chow and 
high-fat diet (HFD)-fed sedentary and exercised gp130Δadipo mice (12; 13; 28). The level 
of UCP1 was unchanged in inguinal (ing) WAT of chow fed mice and undetectable in the 
less browning-prone epididymal (epi) WAT irrespective of diet and genotype 
(Supplementary Fig. 1B-D). However, UCP1 protein levels were significantly elevated in 
ingWAT of HFD-fed gp130Δadipo mice compared to littermate controls (Fig. 1A-B). 
Similarly, UCP1 protein levels and number of multi-locular cells were increased in ingWAT 
of exercised HFD-fed gp130Δadipo mice, as illustrated by Western blot and histological 
analysis, respectively (Supplementary Fig. 1E-F). As expected, 12 weeks of HFD feeding 
markedly lowered Ucp1 mRNA and UCP1 protein levels in ingWAT of control mice 
(Supplementary Fig. 1G-H). The above data infer that HFD-fed gp130Δadipo mice are partly 
protected from such decline in UCP1. To corroborate the latter observation we performed 
complementary gene expression analysis of ingWAT depots from HFD-fed mice and 
found increased Ucp1 mRNA levels in knockout compared to control mice. Moreover, the 
transcripts of additional browning-related markers including Cidea, Pgc-1α (Ppargc1a) 
and Tbx1 were significantly elevated (Fig. 1C). Of note, no significant difference in UCP1 
protein level was detected when comparing BAT depots of gp130Δadipo and gp130F/F mice 
fed either regular chow (Supplementary Fig. 1A) or HFD (28). Together, these results 
indicate that while gp130 depletion may not affect thermogenic potential of classical BAT, 











Although we previously reported that neither body weight nor energy expenditure 
were significantly different between HFD-fed gp130Δadipo and gp130F/F mice (12; 28), we 
hitherto analyzed 17 HFD-fed litters of both genotypes (n=43 mice for gp130F/F; n=35 mice 
for gp130Δadipo) and observed that the average body weight per litter was significantly 
reduced in gp130Δadipo mice (-4.3±1.7% body weight; p=0.02). Importantly, body weight 
negatively correlated with Ucp1 expression in ingWAT of HFD-fed mice (Fig. 1D), 
suggesting that the observed increase in browning contributed to reduced weight gain. 
We next assessed levels of phosphorylated ERK1/2 (p-ERK1/2) and STAT3 (p-
STAT3), both representing key proteins in the signaling cascades downstream of the 
gp130 receptor complex (11). Levels of p-ERK1/2 and p-STAT3 were distributed rather 
heterogeneously in ingWAT of HFD-fed gp130Δadipo and gp130F/F mice (Fig. 1A). 
Correlative analysis showed that p-STAT3 but not p-ERK1/2 negatively associated with 
UCP1 (Fig. 1E-F), suggesting a possible involvement of the STAT3 signaling pathway in 
the regulation of Ucp1 transcription.  
 
3.2 OSM dose-dependently lowers isoproterenol-induced UCP1 levels in cultured 
adipocytes  
As outlined above, the gp130 cytokine family members IL-6 and OSM are elevated 
in obesity and may impact on UCP1 levels (18-20; 29). Moreover, the adipokine leptin, 
secretion and circulating levels of which were reduced in HFD-fed gp130Δadipo mice (12), 
may modulate WAT browning (30-32). Expression of the gp130 downstream mediator and 
potential suppressor of WAT browning autotaxin (gene name Enpp2) (33; 34) was not 
different between both genotypes in ingWAT (Fig. 1C) and, thus, seemed unlikely to 











three other candidates on browning was evaluated using a mouse-derived subcutaneous 
white adipocyte cell line. Basal Ucp1 mRNA and UCP1 protein levels were low and 
remained unchanged upon stimulation with either OSM or IL-6 (Supplementary Fig. 2A, 
2B). The subsequent induction of browning by the β3-adrenoreceptor agonist 
isoproterenol strongly induced UCP1 expression, as expected. Intriguingly, whilst no 
change in isoproterenol-mediated induction of UCP1 level was noted when adipocytes 
were stimulated with IL-6 or leptin, a dose-dependent reduction was observed upon 
incubation with OSM (Fig. 2A-B; Supplementary Fig. 2C). OSM elicited comparable 
effects in a second adipocyte cell line, 3T3-L1 cells, by dose-dependently lowering Ucp1 
gene expression induced by isoproterenol treatment (Fig. 2C). These results indicate that 
OSM suppresses isoproterenol-induced UCP1 levels in cultured white adipocytes and, 
thus, suggest that elevated WAT browning in HFD-fed gp130Δadipo mice can at least in part 
be attributed to their lack in OSM signaling. 
Within the adipose tissue depot, immune cells are the main source of OSM and may 
be responsible for its increased levels under obesity (20; 35). In line, we found higher Osm 
gene expression in the immune-cell containing SVF compared to adipocytes isolated from 
wild-type mice. Moreover, Osm expression tended to be elevated in samples from HFD-
fed compared to chow-fed mice (Supplementary Fig. 3A). In contrast, no major differences 
were observed in gp130 mRNA levels between the two cell fractions irrespective of diet 
(Supplementary Fig. 3B). We hypothesized that an inflammatory milieu as commonly 
present in fat depots under obesity may trigger OSM production in local immune cells. To 
test our hypothesis, we stimulated SVF cells isolated from WAT of wild-type mice with 
LPS. Indeed, LPS-treated SVF cells exhibited significantly higher Osm gene expression 











induced upregulation of Osm was found in RAW cells, a macrophage cell line 
(Supplementary Fig. 3D), rendering macrophages a plausible source of increased OSM 
production in WAT under obesity. 
 
3.3 Inhibition of STAT3 activation prevents OSM-mediated reduction in Ucp1 expression 
OSM was shown to inhibit pre-adipocyte differentiation (36) and to induce 
dedifferentiation of mature adipocytes (37), possibly providing an alternative explanation 
for the OSM-mediated reduction in UCP1 expression. Therefore, we assessed the amount 
of lipid droplets by means of Oil-Red-O staining and determined levels of the adipocyte 
differentiation marker PPARγ in cultured white adipocytes after OSM treatment. As 
depicted in Fig. 3A and Supplementary Fig. 4A-B, no changes in lipid droplet content and 
PPARγ protein and mRNA levels were observed in OSM-treated subcutaneous 
adipocytes compared to vehicle-treated control cells. Of note, in 3T3-L1 adipocytes 
PPARγ mRNA and protein levels were reduced after incubation with 100 ng/ml but not 
with lower doses of OSM (Supplementary Fig. 4C-F). Moreover, OSM treatment blunted 
insulin-induced phosphorylation of Akt in 3T3-L1 cells (Supplementary Fig. 4E and G), 
suggesting that OSM impacts on insulin signaling in white adipocytes. Collectively, these 
data indicate that a high OSM concentration may induce adipocyte dedifferentiation as 
previously described (37).  
To elucidate whether ERK1/2 and/or STAT3 activation may contribute to OSM-
mediated reduction in UCP1 expression, p-ERK1/2 and p-STAT3 abundance was 
assessed in mature subcutaneous adipocytes treated with OSM for different durations. As 
shown in Fig. 3A-C, OSM induced ERK1/2 phosphorylation after 15 minutes but 











independently study the contribution of the ERK and the STAT pathway to the action of 
OSM, we used the MEK inhibitor U0126 and the JAK inhibitor Tofacitinib, respectively. As 
expected, U0126 successfully prevented ERK1/2 phosphorylation while Tofacitinib 
completely blocked STAT3 activation (Fig. 3D). Pre-incubating subcutaneous adipocytes 
with U0126 had no effect on the OSM-mediated blunting of Ucp1 mRNA levels (Fig. 3F). 
Conversely, Tofacitinib partially restored Ucp1 mRNA expression (Fig. 3F). Thus, our data 
suggests that OSM suppresses browning in subcutaneous adipocytes JAK-STAT3 
dependently.  
 
3.4 OSM positively correlates with BMI but negatively with UCP1 in human 
subcutaneous WAT 
To ascertain the clinical relevance of our mouse data, we measured OSM gene 
expression in subcutaneous fat biopsies from a cohort of lean and obese human subjects. 
A moderate but significant positive correlation between OSM mRNA levels and BMI was 
found (Fig. 4A). As expected, IL-6 mRNA level also showed a similar positive correlation 
whereas UCP1 gene expression negatively correlated with BMI (Fig. 4B, 4C). 
Furthermore, while no linear relationship between UCP1 and IL-6 gene expression levels 
was observed, UCP1 negatively correlated with OSM expression (Fig. 4D, 4E). These 
results support our mouse data and indicate that elevated levels of OSM associated with 














Impaired WAT thermogenesis, i.e. the capacity of WAT to undergo browning, may 
contribute to the development and/or maintenance of obesity (38). Herein, we provide 
evidence that OSM may add to blunted WAT browning. In both mice and humans, 
increased adiposity is associated with a surge of proinflammatory cytokines including 
OSM in fat depots (20; 39). We simulated this in vivo observation by cultivating 
subcutaneous adipocytes in the presence of different OSM concentrations and observed 
a dose-dependent blunting of the main thermogenic marker UCP1. Conversely, 
expression of UCP1 and other browning markers was enhanced in ingWAT depots of 
HFD-fed gp130Δadipo mice with blocked OSM signaling. Clearly, we cannot exclude that 
other metabolic changes and/or other gp130 cytokines than OSM contributed directly or 
indirectly to the observed changes in ingWAT browning. Our human data confirms a 
previous small-scale study indicating that OSM is increased in subcutaneous WAT of 
people with obesity (20) and suggests that, in conjunction with our mouse data, obesity-
induced OSM impairs WAT browning. In support of a physiological significance of such 
finding, Ucp1 expression in WAT correlated negatively with body weight and BMI in mice 
and men, respectively, suggesting that elevated OSM levels contribute to increased body 
weight in both species. Of note, the gp130Δadipo mouse exhibits a complex phenotype that, 
besides direct effects on adipocytes, includes indirect metabolic changes in gut, 
pancreatic islets, liver and hypothalamus (12; 13; 28). In particular, knockout mice 
revealed reduced circulating levels of insulin and leptin, two factors that are critically 
involved in the regulation of energy expenditure and/or body weight (40; 41). Accordingly, 
such changes may have prevented a clearer effect on body weight and/or energy 











gain is heterogeneous, with some cohorts/litters being more resistant than others. In the 
current re-analysis, we included about twice as many litters compared to our initial 
analysis and found that the average body weight per litter was significantly reduced in 
HFD-fed knockout mice, supporting the notion that increased browning in knockout mice 
reduces body weight.  
A more selective model to study OSM signaling in vivo is the adipocyte-specific OSM 
receptor knockout mouse (OSMRΔadipo) (35). The OSM receptor dimerizes with a gp130 
subunit to form the OSM receptor complex. Of note, the OSMRΔadipo mouse does not only 
block signaling of OSM but also of IL-31, as the latter also contains an OSMR subunit in 
its receptor complex (42; 43). Whether the OSMRΔadipo mouse also exhibits increased 
browning in ingWAT has not been reported. However, OSMRΔadipo mice are more sensitive 
to diet-induced obesity and display increased adipose tissue inflammation and insulin 
resistance (35). Hence, this phenotype clearly differs from the one of gp130Δadipo mice, 
which may be expected from the molecular difference between the two models. While 
OSM action is prevented in either model, it is accompanied by blocking of IL-31 signaling 
in the OSMRΔadipo mouse and via interfering with gp130 signaling in the gp130Δadipo mouse.  
Using an in vitro model of WAT browning, we observed no direct effects of IL-6 and 
leptin on UCP1 expression. Considering that both IL-6 and leptin, like OSM, can signal 
via the JAK-STAT3 pathway, the question arises why OSM and not IL-6 or leptin mediates 
Ucp1 transcription. One possibility is that their common negative regulator SOCS3 acts 
differently depending whether it is activated by OSM or by the other two factors. While 
SOCS3 was shown to prevent IL-6 mediated STAT3 phosphorylation after two hours (44), 
we observed herein that OSM promotes sustained activation of STAT3 up to 24 hours, 











explanations may include differential cross-talk with other cytokines (45) or differences in 
localization or composition of the receptors. It should be noted that, in contrast to OSM, 
IL-6 and leptin are generally considered positive regulators of WAT browning. For 
instance, more WAT browning was found after systemic IL-6 treatment (18) or in mouse 
models of cancer where IL-6 was upregulated under conditions of cachexia (19). Leptin 
likely promotes WAT browning in an indirect manner via signaling through the 
hypothalamus (30; 31). Since systemic leptin concentrations were lower in gp130Δadipo 
mice, we consider it improbable that leptin mediated the observed induction of ingWAT 
browning. Initially, we also hypothesized that the adipocyte-derived enzyme autotaxin may 
have contributed to elevated browning in gp130Δadipo mice, especially since an obesity-
associated increase in gp130 signaling upregulated autotaxin in adipose tissue (34) and 
mice that transgenically overexpressed autotaxin displayed reduced browning in WAT 
(33). Yet, the observation that autotaxin levels in ingWAT were not different between HFD-
fed gp130Δadipo and gp130F/F mice infers an insignificant role of autotaxin on the browning 
phenotype in our mouse model.  
The present study confirms previous work (20; 29) showing that Osm levels are 
elevated in adipose tissue of obese mice, likely due to an altered gene expression in the 
non-adipocyte fraction. We further find that an LPS-mediated inflammatory response 
induced Osm gene expression in SVF cells as well as cultured macrophages, providing 
one potential mechanism driving such increase. Despite the putatively higher Osm level 
in all fat depots, the unchanged UCP1 expression in BAT of HFD-fed gp130Δadipo mice 
would infer that the inhibitory role of OSM is limited to ingWAT. This notion is underpinned 
by a recent study by Sanchez-Infantes et al., who found that cold-induced upregulation of 











observed when OSM was infused in supraclavicular BAT (29). Besides higher OSM 
levels, increased OSM signaling may be effectuated by elevated OSM sensitivity or 
augmented expression of gp130 and/or OSM receptor (OSMR). However, while OSM was 
shown to induce gp130 and Osmr levels in 3T3-L1 cells (35), we did not find increased 
gp130 mRNA levels in adipocytes of HFD compared to chow-fed mice. Collectively, these 
data suggest that lowering of local OSM secretion and/or signaling in WAT could be a 
potential therapeutic strategy to promote browning and, thus, to combat obesity. In 
contrast, a recent study reported that systemic treatment with OSM improved the 
metabolic phenotype of obese mice (46). This underscores the importance to understand 
the differential role of OSM in various tissues.  
In the current study, we employed Tofacinib to block OSM-mediated STAT3 
signaling in cultured adipocytes. This novel JAK2 inhibitor successfully induced UCP1 
mRNA in human adipocytes (16) and promoted WAT browning in HFD-fed mice (47). 
However, herein we did not observe induction of Ucp1 by Tofacitinib in cultured 
adipocytes. Potentially, isoprotenerol may have masked such effect of Tofacitinib. 
Nonetheless, our findings are in agreement with the conception that JAK2 inhibition in 
white adipocytes may be beneficial in obese conditions. 
In conclusion, our data support the notion that OSM negatively regulates 
thermogenesis in subcutaneous WAT via gp130-STAT3 signaling and, thus, may be an 
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Figure 1 Increased browning in ingWAT of HFD-fed gp130Δadipo mice 
(A) Representative Western blot of respective targets in ingWAT from HFD-fed gp130F/F 
and gp130Δadipo mice. (B) Quantification of UCP1 protein levels in ingWAT of HFD-fed 
gp130F/F (n=11) and gp130Δadipo (n=13) mice. (C) Gene expression levels of respective 
targets in ingWAT from HFD-fed gp130F/F (n=8-11) and gp130Δadipo mice (n=9-14). (D) 
Body weight of HFD-fed gp130F/F and gp130Δadipo mice at time of sacrifice and 
corresponding Ucp1 gene expression level in ingWAT (n=22). (E-F) UCP1 and 
corresponding p-ERK1/2 or p-STAT3 protein levels in ingWAT from HFD-fed gp130F/F and 
gp130Δadipo mice (n=21). Open circles/squares represent individual gp130F/F and 
gp130Δadipo ingWAT samples, respectively. *, p<0.05; **, p<0.01. Panel B, Mann-Whitney 
test; panel C, Student’s t-test; panel D, E and F, Linear Regression analysis. Error bars 
represent S.E.  
 
Figure 2 OSM dose-dependently lowers isoproterenol-induced UCP1 levels in 
cultured adipocytes  
Normalized Ucp1 gene expression and/or UCP1 protein levels of subcutaneous 
adipocytes (A-B) or 3T3-L1 adipocytes (C) cultured in the presence of a vehicle or different 
concentrations of OSM or IL-6 for 24 hours followed by 6 hours of isoproterenol stimulation 
(n=4-8). **, p<0.01; ***, p<0.001 compared to vehicle-treated control. Panel A and B, One-












Figure 3 Inhibition of STAT3 activation prevents OSM-mediated reduction in 
Ucp1 expression 
(A-C) Western blot of subcutaneous white adipocytes stimulated with OSM or vehicle for 
indicated time periods and quantifications of phosphorylated ERK1/2 and STAT3 protein 
levels (n=4). (D) Western blot of subcutaneous white adipocytes stimulated with vehicle 
(control), U0126 (50 μM) or Tofacitinib (2 μM) for 1 hour. (E-F) Ucp1 gene expression 
levels of subcutaneous white adipocytes that were subsequently stimulated with either 
U0126 or Tofacitinib (1 hour), OSM (3 hours) and isoproterenol (3 hours), displayed 
relative to a negative control (left panel) or as a percentage of the internal control with and 
without inhibitor (right panel; n=6-8). *, p<0.05; **, p<0.01; ***, p<0.001. One-way ANOVA 
(E-F, left panel) or Student’s t-test (E-F, right panel). Error bars represent S.E. 
 
Figure 4 OSM positively correlates with BMI but negatively with UCP1 in human 
subcutaneous WAT 
(A-E) Correlations between BMI and OSM, IL-6 or UCP1 mRNA level, and between UCP1 
and OSM or IL-6 mRNA levels (n=66). Gene expression data was obtained from 
subcutaneous human WAT biopsies. Samples with undetectable gene expression levels 
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 OSM is regulated under obesity and negatively correlates with UCP1 in WAT 
 OSM suppresses isoproterenol-induced UCP1 in subcutaneous adipocytes 
 OSM signals through the gp130-STAT3 pathway to lower UCP1 expression 
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